首页> 外文期刊>Antioxidants and redox signalling >Organic nitrates differentially modulate circulating endothelial progenitor cells and endothelial function in patients with symptomatic coronary artery disease.
【24h】

Organic nitrates differentially modulate circulating endothelial progenitor cells and endothelial function in patients with symptomatic coronary artery disease.

机译:有机硝酸盐对有症状冠状动脉疾病患者的循环内皮祖细胞和内皮功能有不同的调节作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Symptomatic coronary artery disease (CAD) is usually treated with organic nitrates. Endothelial progenitor cells (EPCs) are a circulating cell population participating in vascular homeostasis in a nitric oxide-dependent manner. We investigated the effects of the nitric oxide donors isosorbide dinitrate (ISDN) and pentaerythritol tetranitrate (PETN) on EPC and endothelial function in patients with symptomatic CAD. We randomized 36 patients with angiographically proven CAD to treatment with either ISDN (40 mg retarded release orally two times per day; n = 18) or PETN (80 mg orally two times per day; n = 18) for 14 days (clinical trial number: NCT01030367). PETN treatment substantially increased numbers of circulating CD34(+)/KDR(+) EPCs (p = 0.02), whereas no effects were observed in patients treated with ISDN. EPC function assessed by formation of endothelial colonies was enhanced by twofold (p = 0.04) in patients treated with PETN. No changes were observed after ISDN treatment. Endothelial function, assessed by peripheral arterial tonometry, remained unchanged during PETN treatment, but was significantly impaired in patients treated with ISDN. Treatment of symptomatic CAD patients with PETN for 14 days significantly increased levels of circulating EPC and improved markers for EPC function, whereas ISDN was without effects on EPCs and worsened endothelial function.
机译:有症状的冠状动脉疾病(CAD)通常用有机硝酸盐治疗。内皮祖细胞(EPC)是循环细胞群,其以一氧化氮依赖性方式参与血管稳态。我们调查了有症状的CAD患者一氧化氮供体二硝酸异山梨酯(ISDN)和季戊四醇四硝酸酯(PETN)对EPC和内皮功能的影响。我们将36例经血管造影证实为CAD的患者随机分为ISDN(每天两次两次,口服40 mg缓释; n = 18)或PETN(每天两次,两次口服; 80 mg缓释; n = 18)治疗14天(临床试验编号) :NCT01030367)。 PETN治疗显着增加了循环中CD34(+)/ KDR(+)EPC的数量(p = 0.02),而在用ISDN治疗的患者中未观察到效果。在用PETN治疗的患者中,通过内皮集落形成评估的EPC功能提高了两倍(p = 0.04)。 ISDN处理后未观察到任何变化。通过外周动脉眼压计评估的内皮功能在PETN治疗期间保持不变,但在用ISDN治疗的患者中明显受损。有症状的PETN的有症状的CAD患者治疗14天可显着提高循环EPC水平并改善EPC功能标记,而ISDN对EPC无影响且内皮功能恶化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号